Log In
Print this Print this

aflibercept/rinucumab (REGN2176-3) (formerly REGN-2176)

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
DescriptionCo-formulation of Eylea aflibercept, a human fusion protein that binds all forms of VEGF-A and placental growth factor (PGF; PlGF), and rinucumab, a platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) antibody
Molecular Target Platelet derived growth factor receptor B (PDGFRB) (PDGFR1) (CD140B) ; Placental growth factor (PGF) (PlGF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation
PartnerBayer AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today